Moderna, Inc. — News

Explore the exciting world of Moderna (MRNA -5.17%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

fool.com - 2026-07-24 19:00:00

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-07-24 11:01:09

California Public Employees Retirement System raised its position in Moderna, Inc. (NASDAQ: MRNA) by 31.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 628,160 shares of the company's stock after purchasing an additional 149,192 shares during the quarter. California Public Employees

defenseworld.net - 2026-07-22 04:17:47

Moderna is racing towards an important approval. But it may not move the stock higher.

fool.com - 2026-07-21 20:00:00

IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.

fool.com - 2026-07-21 13:32:42

In the most recent trading session, Moderna (MRNA) closed at $59.49, indicating a -3.77% shift from the previous trading day.

zacks.com - 2026-07-20 18:51:14

Moderna is known as a coronavirus vaccine giant, but it's progressively becoming a multi-product company. The biotech has several exciting candidates in late-stage trials.

fool.com - 2026-07-20 18:10:00

Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.

zacks.com - 2026-07-17 12:01:17

CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. mRNA-4200 encodes for seven antigens commonly shared across patients and tumor types and is designed to help induce and expand T-cell responses against selected tumor targets.

accessnewswire.com - 2026-07-16 07:00:00

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19 vaccine demand and updates on the company's late-stage pipeline, including anticipated Phase III melanoma data. Jefferies analysts expect a largely uneventful earnings report after Moderna previously guided for second-quarter revenue of $50 million to $100 million, down from $389 million in the first quarter, reflecting the seasonal nature of COVID vaccine sales.

proactiveinvestors.com - 2026-07-14 13:37:04

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19...

proactiveinvestors.com - 2026-07-14 09:35:00

Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close.

zacks.com - 2026-07-13 18:51:07

Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusiran has shown durable viral control. The main caveat is that it comes from combo therapies. Their balance sheet gives them a comfortable runway to pursue imdusiran's upcoming Phase 2b trial, which is yet another optionality vertical for the stock.

seekingalpha.com - 2026-07-13 08:00:00

Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.

247wallst.com - 2026-07-10 12:04:38

Moderna said on Thursday it has secured a European Commission contract to ​supply its respiratory syncytial virus vaccine ‌to six countries in the region.

reuters.com - 2026-07-09 07:17:59

CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide a corporate update.

accessnewswire.com - 2026-07-09 07:00:00

Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the appointment of Michael McDonnell to its Board of Directors, effective July 8, 2026. Mr. McDonnell will also serve on the Board's Audit Committee.

accessnewswire.com - 2026-07-08 07:00:00

Moderna is no longer just a COVID-19 vaccine company. A growing pipeline could fuel long-term revenue growth.

fool.com - 2026-07-07 05:15:00

Moderna (MRNA) closed at $81.76 in the latest trading session, marking a +2.51% move from the prior day.

zacks.com - 2026-07-06 18:50:17

Each of these biotech players has reached an important turning point. Recent drug approvals could supercharge the performance of one in particular.

fool.com - 2026-07-06 18:10:00

Tom Yeung here with your Sunday Digest . In the days following its IPO, Space Exploration Technologies Corp. ( SPCX ) surged 25%, rewarding early investors and turning its owner, Elon Musk, into a trillionaire.

investorplace.com - 2026-07-05 12:00:00

An FDA advisory panel voted 9-0 that Moderna's mRNA flu vaccine's benefits outweigh its risks. A final approval decision is expected by Aug. 5.

fool.com - 2026-07-03 13:07:00

Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.

zacks.com - 2026-07-03 12:35:16

Moderna is evolving from a COVID-19 vaccine specialist into a multi-product firm with major oncology and rare disease partnerships. Recursion Pharmaceuticals is leveraging artificial intelligence and massive biological datasets to accelerate drug discovery via high-tech collaborations.

fool.com - 2026-07-03 11:14:15

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.

fool.com - 2026-07-03 08:37:20

Moderna Inc. (MRNA) shares rose 9.2% on Thursday, making the biotechnology company among the top performers in the S&P 500 as investors responded positively to new pipeline updates, encouraging influenza vaccine data, and favorable analyst commentary. The stock extended its recent rally after climbing to a new annual high on Wednesday.

invezz.com - 2026-07-02 15:51:56

At that time, Moderna revealed its strategy for using mRNA to combat cancer and rare diseases. It's a move beyond vaccines, and investors seem to like it.

marketbeat.com - 2026-07-01 07:00:16

On June 16, Moderna announced major news regarding one of its most highly anticipated follow-up products: an mRNA-based flu vaccine. The biotech company has also made some other promising announcements in recent weeks.

fool.com - 2026-06-30 14:15:00

Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.

zacks.com - 2026-06-29 14:06:07

Moderna, Inc.  (NASDAQ:MRNA) shares are trading higher on Monday. This follows Friday's gain of more than 12%.

benzinga.com - 2026-06-29 10:03:21

Moderna Inc. (MRNA) shares surged nearly 10% on Friday, extending a powerful rally that has lifted the stock about 40% over the past month and significantly outperformed the broader market. The gains followed the company's Science Day presentation and investor event, where Moderna outlined an ambitious strategy to expand beyond its COVID-19 vaccine business and build a diversified portfolio spanning oncology, autoimmune diseases, and next-generation mRNA therapies.

invezz.com - 2026-06-26 14:47:34

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer.

247wallst.com - 2026-06-26 12:01:13

Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.

barrons.com - 2026-06-26 11:36:00

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - Investorideas.com, a leading investment platform for retail investors

feeds.newsfilecorp.com - 2026-06-26 07:00:00

It's not just a "pandemic stock," after all.

fool.com - 2026-06-26 01:00:00

Moderna, Inc. (MRNA) Discusses Advancements in mRNA Technology, Clinical Modalities, and Future Horizons in Science Transcript

seekingalpha.com - 2026-06-25 21:32:11

Provides broad overview of Company's research and early development programs expected to continue to fuel future growth Highlights validation of T-cell engager modality with mRNA-2808 in multiple myeloma, supporting rapid advancement of second T-cell engager mRNA-2151 in ovarian cancer Introduces in vivo CAR-T modality with mRNA-6007 moving into early development for autoimmune diseases CAMBRIDGE, MA / ACCESS Newswire / June 25, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced research and early development updates at its Science Day event. "As we execute our strategic plan to become a diversified, multi-modality biotechnology company, we are preparing to manage three commercial franchises, Infectious Disease Vaccines, Intismeran, and Rare Disease Therapeutics, while advancing a broad mRNA pipeline and continuing to invest in research and development," said Stéphane Bancel, CEO of Moderna.

accessnewswire.com - 2026-06-25 07:00:00

Moderna (MRNA) closed at $61 in the latest trading session, marking a +2.79% move from the prior day.

zacks.com - 2026-06-23 18:51:05

Stocks are continuing lower amid the global tech selloff, with the Nasdaq Composite (IXIC) off nearly 500 points

schaeffersresearch.com - 2026-06-23 12:18:00

Investors flocked to Moderna during early pandemic days as its coronavirus vaccine delivered blockbuster revenue. Since, times have been tough for Moderna, but the company may have reached an important turning point.

fool.com - 2026-06-22 18:10:00

Modera grew revenue by 260% year over year in the first quarter. The company is trying its mRNA platform in oncology vaccines.

fool.com - 2026-06-20 07:30:00

Moderna stock gains 3.5% after FDA advisory panel votes 9-0 that mFlusiva's benefits outweigh risks in influenza prevention in older adults, ahead of an Aug. 5 decision.

zacks.com - 2026-06-19 09:06:05

Moderna said the FDA's Vaccines and Related Biological Products Advisory Committee voted unanimously that the benefits of the vaccine, mRNA-1010, exceed the risks for the prevention of flu in adults 50 through 64 years old, and in adults 65 years of age and older.

wsj.com - 2026-06-18 16:23:00

FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026 CAMBRIDGE, MA / ACCESS Newswire / June 18, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 9-0 that the benefits of mRNA-1010, Moderna's investigational seasonal influenza vaccine, outweigh its risks for the prevention of influenza disease in adults 50 through 64 years of age and voted 9-0 that the benefits of mRNA-1010 outweigh its risks for the prevention of influenza disease in adults 65 years of age and older. "We appreciate the thoughtful review by the members of VRBPAC and their recognition of the clinical evidence supporting mRNA-1010," said Stéphane Bancel, Chief Executive Officer of Moderna.

accessnewswire.com - 2026-06-18 16:00:00

The U.S. Food ​and Drug Administration's advisers on ‌Thursday backed approval of ​Moderna's flu ​vaccine in adults aged ⁠50 ​and older, saying ​its benefits outweigh the risks.

reuters.com - 2026-06-18 14:48:30

The U.S. Food and Drug Administration's advisory panel is set to vote on whether the benefits of Moderna's flu vaccine outweigh its risks in older adults, after regulators reversed course ​on rejecting the drugmaker's initial application for the shot.

reuters.com - 2026-06-18 06:01:39

Moderna is racing towards important clinical and regulatory catalysts. Krystal Biotech still has a large market to address in its core area.

fool.com - 2026-06-18 01:30:00

Moderna jumps after FDA briefing documents on mFlusiva appear more constructive than expected ahead of a key advisory panel review.

zacks.com - 2026-06-17 12:16:13

Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

zacks.com - 2026-06-17 10:15:35

The U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet on Thursday, June 18, to discuss approval of Moderna Inc.'s (NASDAQ:MRNA) experimental mRNA-based flu vaccine.

benzinga.com - 2026-06-17 08:23:52